RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. (RAPT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rapt · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for RAPT Therapeutics, Inc. (RAPT) measures how much investors pay for each dollar of the company's trailing earnings. RAPT's current PE ratio of N/A is calculated by dividing its stock price of $58.01 by its TTM earnings per share of -$3.92.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2017 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
RAPT Therapeutics, Inc.You RAPT | $959M | N/A | — | -$3.92 |
 ADC Therapeutics S.A. ADCT | $129M | N/A | — | -$1.12 |
 Alumis Inc. Common Stock ALMS | $2.4B | N/A | — | -$0.29 |
 Bicycle Therapeutics plc BCYC | $285M | N/A | — | -$3.16 |
 4D Molecular Therapeutics, Inc. FDMT | $452M | N/A | — | -$2.42 |
 Fulcrum Therapeutics, Inc. FULC | $190M | N/A | — | -$1.18 |
 Gossamer Bio, Inc. GOSS | $39M | N/A | — | -$0.75 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-25.49 | — | |
2023-12-31 FY2023 | — | $-24.37 | — | |
2022-12-31 FY2022 | — | $-20.61 | — | |
2021-12-31 FY2021 | — | $-20.21 | — | |
2020-12-31 FY2020 | — | $-17.53 | — | |
2019-12-31 FY2019 | — | $-15.75 | — | |
2018-12-31 FY2018 | — | $-13.59 | — | |
2017-12-31 FY2017 | — | $-10.95 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for RAPT Therapeutics, Inc. (RAPT) measures how much investors pay for each dollar of the company's trailing earnings. RAPT's current PE ratio of N/A is calculated by dividing its stock price of $58.01 by its TTM earnings per share of -$3.92.
Frequently asked questions
RAPT pe ratio · 6 questionsRAPT's current PE ratio is N/A as of 2026-06-09, based on a stock price of $58.01 and TTM EPS of -$3.92. Data sourced from Financial Modeling Prep via RAPT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · RAPT Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09